Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

All products: not a benefit

Other products in the same Health Canada class (D01A, D01AC) — coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, Not a benefit
  • Ketoconazole (Nizoral): general benefit, Not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Nystatin (Mycostatin): general benefit, Not a benefit
  • Terbinafine (Lamisil): general benefit
  • Ciclopirox (Penlac): not a benefit

TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · 1% w/w & 0.05% w/w · Top Cr

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-06-30 Health Canada: Marketed since 2020-04-06 · brand TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W, CLOTRIMAZOLE 1 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629 · Verify on the e-Formulary ↗ (DIN 02496410)

Source record
DIN 02496410: TaroClotrimazole/BetamethasoneDipropiona Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id TAR Source form: Top Cr; strength: 1% w/w & 0.05% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0832; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496410 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629
Interchangeable products
Lotriderm Cream · DIN 00611174 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LOTRIDERM® Cream (betamethasone dipropionate and clotrimazole) is indicated for:  the topical treatment of the following fungal dermal infections complicated by inflammatory pruritus: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. 1.1 Pediatrics Pediatrics: Based on the available data, the safety and effectiveness in children below the age of 12 have not been established with LOTRIDERM® Cream. 1.2 Geriatrics Geriatrics: There is insufficient data to suggest that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00060782.PDF PM date: April 20, 2021 Source product: LOTRIDERM; DIN 00611174; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For TaroClotrimazole/BetamethasoneDipropiona: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026